



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Nidanilimab

Cat. No.:	HY-P99379
CAS No.:	2171061-85-9
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a $K_D$ value of 1.10 pM. Nidanilimab blocks IL1 $\alpha$ and IL1 $\beta$ signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) <sup>[1][2]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	IL-1 $\alpha$	IL-1 $\beta$								
<b>In Vitro</b>	<p>Nidanilimab (CAN04; 20 <math>\mu</math>g/mL; murine MC38 colon cancer cells) has glycoengineered to mediate an enhanced antibody-dependent cellular cytotoxicity (ADCC, EC<sub>50</sub>&lt;1 nM)<sup>[2]</sup>.</p> <p>Nidanilimab (20 <math>\mu</math>g/mL; murine MC38 colon cancer cells) blocks IL1<math>\alpha</math> and IL1<math>\beta</math> signaling with IC<sub>50</sub> values of 3.9 nM and 4.1 nM, respectively.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of <a href="#">Cisplatin</a> (HY-17394)/<a href="#">Gemcitabine</a> (HY-17026) and <a href="#">Carboplatin</a> (HY-17393)/<a href="#">Gemcitabine</a> (HY-17026), two commonly used platinum-based chemotherapies<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Nude C57Bl/6 mice with LU2503 NSCLC PDX model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection</td> </tr> <tr> <td>Result:</td> <td>Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.</td> </tr> </table>		Animal Model:	Nude C57Bl/6 mice with LU2503 NSCLC PDX model <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection	Result:	Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.
Animal Model:	Nude C57Bl/6 mice with LU2503 NSCLC PDX model <sup>[1]</sup>									
Dosage:	10 mg/kg									
Administration:	Intraperitoneal injection									
Result:	Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy.									

### REFERENCES

[1]. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.

[2]. Rydberg Millrud C, et, al. Blockade of IL-1 $\alpha$  and IL-1 $\beta$  signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA